What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025BloodOpen Access

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Combination of IgG2a 4-1BB agonist and S100A9 inhibition reduces plasmacytosis in multiple myeloma, suggesting improved tumor control.

Significant reduction in plasmacytosis to 14.09% with combination therapy in preclinical multiple myeloma model.
Treatment with IgG2a-formatted 4-1BB agonist resulted in enhanced T cell activation and decreased myeloid-derived suppressor cells.
Assessment included flow cytometry and analysis of tumor microenvironment changes in response to treatment.
Findings underscore the importance of select agonists and combinations in targeting tumor microenvironment for immunotherapy.

Menu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Combination of IgG2a 4-1BB agonist and S100A9 inhibition reduces plasmacytosis in multiple myeloma, suggesting improved tumor control.

Significant reduction in plasmacytosis to 14.09% with combination therapy in preclinical multiple myeloma model.
Treatment with IgG2a-formatted 4-1BB agonist resulted in enhanced T cell activation and decreased myeloid-derived suppressor cells.
Assessment included flow cytometry and analysis of tumor microenvironment changes in response to treatment.
Findings underscore the importance of select agonists and combinations in targeting tumor microenvironment for immunotherapy.

Menu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark